Analyse produit facultative
Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
Bio-Rad Laboratories, Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $9.7B |
|---|
| Revenue (ttm) | 2.6B |
|---|
| Net income (ttm) | 222.4M |
|---|
| EPS (ttm) | $8.26 |
|---|
| Shares out | 26.7M |
|---|
| P/E (trailing) | 46.5x |
|---|
| P/E (forward) | 41.3x |
|---|
| Volume | 190,866 |
|---|
| Beta | 1.07 |
|---|
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $2.92B | $2.80B | $2.67B | $2.57B | $2.58B | -3.0% |
| Gross profit | $1.64B | $1.57B | $1.43B | $1.38B | $1.34B | -4.9% |
| Operating income | $500.3M | $482.6M | $337.8M | $269.0M | $47.2M | -44.6% |
| Net income | $4.25B | $-3.63B | $-637.3M | $-1.84B | $759.9M | -35.0% |
| EPS (diluted) | $140.83 | $-39.59 | $-21.82 | $-65.36 | $27.85 | -33.3% |
| EBITDA | $5.59B | $-4.53B | $-654.8M | $-2.14B | $1.21B | -31.8% |
| R&D | $260.6M | $256.9M | $247.4M | $295.9M | $275.6M | +1.4% |
| SG&A | $877.1M | $827.8M | $841.7M | $814.0M | $844.3M | -0.9% |
Recent company headlines from major financial publishers.
In the base case, Clinical Diagnostics quality controls and blood typing generate steady recurring cash flows, offsetting near-term instrument weakness in Life Science. Operating margins expand modestly in FY2027 and normalize through FY2030 as operating expense rationalization takes hold. Consolidated revenue growth inflects higher after FY2027. Intrinsic valuation yields a central Fair value of $164.82 per share.
In the bull case, biopharma research funding experiences a rapid recovery in FY2027, unlocking pent-up demand for Life Science instruments. Catalog assay migration onto Stilla ddPCR platforms drives strong consumable growth, while facility restructuring delivers faster-than-expected margin leverage. Operating margins expand beyond guidance toward upper-teen levels, supporting strong earnings growth.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.5% | $177 | $180 | $184 | $188 | $192 |
| 9.0% | $168 | $171 | $174 | $177 | $181 |
| 9.5% | $160 | $162 | $165 | $168 | $171 |
| 10.0% | $153 | $155 | $157 | $159 | $162 |
| 10.5% | $146 | $148 | $150 | $152 | $154 |
Upcoming earnings date and setup when available.
La notation portée par l'édition de recherche publiée chaque mois. Une notation compare le cours à la date d'analyse à la juste valeur ; elle n'indique pas si l'appréciation s'est révélée juste.
| Année | janv. | févr. | mars | avr. | mai | juin | juil. | août | sept. | oct. | nov. | déc. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
